Vinorelbine
- Generic Name
- Vinorelbine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C45H54N4O8
- CAS Number
- 71486-22-1
- Unique Ingredient Identifier
- Q6C979R91Y
- Background
Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) . It was initially approved in the USA in 1990's for the treatment of NSCLC .
...
- Indication
Vinorelbine tartrate is indicated for adults in the treatment of advanced non-small cell lung cancer (NSCLC), as a single therapy or in combination with other chemotherapeutic drugs .
Used in relapsed or refractory Hodgkin lymphoma, in combination with other chemotherapy agents .
...
- Associated Conditions
- Locally Advanced Non-Small Cell Lung Cancer, Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Non-Small Cell Lung Cancer, Recurrent Cervical Cancer, Soft Tissue Sarcoma
- Associated Therapies
- -
Bevacizumab in Combination With Vinorelbine and Trastuzumab for HER2-Positive, Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-05-02
- Last Posted Date
- 2013-05-13
- Lead Sponsor
- Harold J. Burstein, MD, PhD
- Target Recruit Count
- 29
- Registration Number
- NCT00670982
- Locations
- 🇺🇸
Hartford Hospital, Hartford, Connecticut, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)
- Conditions
- Interventions
- Drug: GemcitabineDrug: NavelbineDrug: Doxorubicin Hydrochloride Liposome InjectionDrug: Granulocyte-colony stimulating factor (G-CSF)Drug: PegfilgrastimDrug: CyclophosphamideDrug: VincristineDrug: LeucovorinDrug: MethotrexateDrug: Doxorubicin HydrochlorideDrug: CytarabineDrug: EtoposideDrug: CarmustineDrug: Denileukin diftitox
- First Posted Date
- 2008-03-11
- Last Posted Date
- 2020-04-27
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 21
- Registration Number
- NCT00632827
- Locations
- 🇺🇸
Washington University, Saint Louis, Missouri, United States
Cisplatin/Vinorelbine/Bevacizumab Followed by Docetaxel/Gemcitabine/Bevacizumab Versus the Cisplatin/Docetaxel/Bevacizumab Combination in Locally Advanced or Metastatic NSCLC
- Conditions
- Interventions
- First Posted Date
- 2008-02-22
- Last Posted Date
- 2014-06-25
- Lead Sponsor
- Hellenic Oncology Research Group
- Target Recruit Count
- 77
- Registration Number
- NCT00620971
- Locations
- 🇬🇷
Sismanogleio General Hospital, 1st, 2nd Dep of Pulmonary Diseases, Athens, Greece
🇬🇷"Laikon" General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine, Athens, Greece
🇬🇷IASO" General Hospital of Athens, 1st Dep of Medical Oncology, Athens, Greece
An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma
- First Posted Date
- 2008-01-17
- Last Posted Date
- 2016-10-10
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 25
- Registration Number
- NCT00597116
- Locations
- 🇨🇭
Research Site, Zurich, Switzerland
Lapatinib and Vinorelbine in Treating Women With HER2-Overexpressing Locally Advanced or Metastatic Breast Cancer
- First Posted Date
- 2007-08-08
- Last Posted Date
- 2014-01-14
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 33
- Registration Number
- NCT00513058
- Locations
- 🇫🇷
Centre de Lutte Contre le Cancer Georges-Francois Leclerc, Dijon, France
🇫🇷Centre Oscar Lambret, Lille, France
🇫🇷Institut Curie Hopital, Paris, France
Phase II Neoadjuvant Trial of Trastuzumab in Combination With Dose-Dense ABI-007 (Abraxane™)
- Conditions
- Interventions
- First Posted Date
- 2007-07-19
- Last Posted Date
- 2012-06-25
- Lead Sponsor
- Emory University
- Target Recruit Count
- 27
- Registration Number
- NCT00503750
- Locations
- 🇺🇸
Piedmont Hospital Research Institute, Atlanta, Georgia, United States
🇺🇸Emory University Winship Cancer Institute, Atlanta, Georgia, United States
Phase III of RRM1 & ERCC1 Directed Customized Chemotherapy for the Treatment of Patients With NSCLC
- Conditions
- Interventions
- First Posted Date
- 2007-07-11
- Last Posted Date
- 2014-07-09
- Target Recruit Count
- 275
- Registration Number
- NCT00499109
- Locations
- 🇺🇸
Leesburg Regional Medical Center, Leesburg, Florida, United States
🇺🇸Center for Cancer Care & Research/Watson, Lakeland, Florida, United States
🇺🇸Johns Hopkins Sidney Kimmell Comprehensive Cancer Center, Baltimore, Maryland, United States
Gemcitabine/Vinorelbine Versus Gemcitabine/Cisplatin Versus Gemcitabine/Capecitabine in Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2007-05-31
- Last Posted Date
- 2010-10-28
- Lead Sponsor
- Ludwig-Maximilians - University of Munich
- Target Recruit Count
- 141
- Registration Number
- NCT00480597
Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2007-05-22
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- Sally Arai
- Target Recruit Count
- 22
- Registration Number
- NCT00477035
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-04-03
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 71
- Registration Number
- NCT00455572
- Locations
- 🇬🇧
GSK Investigational Site, Southampton, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.